CNO Financial (CNO) stock price is $54.06, down 1.19% on the day, as of Oct 19, 2026. It has a market cap of $5.03Bn and a P/E ratio of 18.00, and is classified in the Life Insurance industry (Financial Services sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap5.03 Bn
P/E18.00
P/S1.08
Div. Yield0.00
Total Debt (Qtr)1.34 Bn
Revenue Growth (1y) (Qtr)11.61
Add ratio to table…
About
CNO Financial Group, Inc. is a holding company for a group of insurance companies that develop, market and administer health insurance, annuity, individual life insurance and other insurance and financial services products. The company focuses on serving middle-income pre-retiree and retired Americans, which it views as attractive, underserved, high-growth markets. As of December 31, 2025, CNO had total assets of $38.8 billion and shareholders' equity of $2.6 billion.
CNO…
CNO Financial Group, Inc. is a holding company for a group of insurance companies that develop, market and administer health insurance, annuity, individual life insurance and other insurance and financial services products. The company focuses on serving middle-income pre-retiree and retired Americans, which it views as attractive, underserved, high-growth markets. As of December 31, 2025, CNO had total assets of $38.8 billion and shareholders' equity of $2.6 billion.
CNO generates revenue primarily through premium collections from its insurance products and investment and fee income. In 2025, the company reported premium collections of $4.5913 billion, driven by sales of annuities, health insurance and life insurance products. These products are distributed through exclusive agents, independent producers and direct marketing channels, with the Consumer and Worksite Divisions reflecting the two primary customer segments served.
The company operates through the following segments: Annuities, Health and Life.
Annuities: This segment includes fixed indexed annuities, fixed interest annuities and other annuity products such as single premium immediate annuities. Fixed indexed annuities accounted for $1,739.9 million in premium collections during 2025, representing 38 percent of total premiums. The company offers branded products under its Bankers Life, Washington National and Colonial Penn names, featuring options like guaranteed lifetime income riders and death benefit riders that provide policyholders with guaranteed income streams or return of premium benefits.
Health: This segment comprises supplemental health, Medicare supplement and long-term care insurance products. Supplemental health collected premiums were $744.5 million in 2025, or 16 percent of total premiums, and includes cancer insurance, heart/stroke policies, accident products and hospital indemnity products. Medicare supplement premiums reached $626.8 million in 2025, or 14 percent of total premiums, with plans that automatically adjust to reflect changes in Medicare benefits, primarily marketed to individuals newly eligible for Medicare.
Life: This segment consists of interest-sensitive life and traditional life insurance products. Interest-sensitive life products, including universal life and fixed indexed universal life, accounted for $255.8 million in premium collections during 2025, or 6 percent of total premiums. Traditional life products, encompassing whole life, graded benefit life, term life and single premium whole life, generated $728.7 million in premiums in 2025, or 16 percent of total premiums, with graded benefit life targeting individuals aged 50 to 85 and single premium whole life requiring one lump sum payment for lifetime coverage.
CNO operates in a competitive insurance landscape where it faces larger rivals with greater capital, technological resources and brand recognition. The company competes primarily on pricing, service provided to distributors and policyholders, and financial strength ratings from agencies such as AM Best, Fitch, Moody’s and S&P. Its main competitors vary by product line, including Northwestern Mutual and Mutual of Omaha for long-term care, United HealthCare and Blue Cross and Blue Shield for Medicare supplement, and AFLAC, Unum and MetLife for supplemental health products sold through the Worksite Division.
CNO serves middle-income pre-retiree and retired Americans, focusing on individuals seeking health insurance, annuity and life insurance solutions for retirement and financial security. The company markets its products to individual consumers through its Consumer Division and to businesses, associations and membership groups via its Worksite Division, which sells voluntary insurance benefits in the workplace. Specific customer concentrations include residents of Florida, Iowa, Texas, California and Pennsylvania, each accounting for at least five percent of 2025 collected premiums.
Sectors:Financial Services·HealthcareSector rationaleThe company's primary revenue is generated through the sale of annuities and life insurance products, which are core financial services activities involving risk management and asset management. A secondary sector of Healthcare is justified because the company has a substantial, distinct business line providing supplemental health, Medicare supplement, and long-term care insurance, which are medical-related insurance products.Industries:Life InsuranceLife InsurancePrimaryCNO Financial operates as a holding company for insurance companies that underwrite life insurance and annuity products. Specifically, it generates significant revenue from traditional life products (whole life, term life) and fixed indexed annuities, managing the long-duration liabilities associated with these contracts.Managed CareManaged CareSecondaryThe company has a dedicated Health segment that collects premiums for supplemental health, Medicare supplement, and long-term care insurance products. These activities involve providing managed-care and health insurance plans to middle-income pre-retirees and retired Americans.Classified using BQ-MICSCIK: 0001224608
Bull & bear
Investment Thesis
▲ Bull case
CNO Financial Group's Medicare Supplement (MedSup) business represents a significant underappreciated catalyst for sustained margin expansion, with approved rate increases set to drive meaningful earnings acceleration in the second half of 2026 and beyond. Management disclosed approvals for a 10.2% rate increase on the closed block (representing two-thirds of exposure) effective January 1, 2026, and expects approximately 14.5% approvals on the open block effective July 1, 2026. These increases are designed to address modestly adverse claims experience and will fully impact benefit ratios by Q4 FY26, with the potential to generate meaningful operating leverage as the company laps tougher comparables in subsequent quarters. Crucially, the shift away from Medicare Advantage—underscored by industry disruption where approximately 3 million MA members had plans terminated for 2026 and one in five beneficiaries switched plans during AEP—creates a structural tailwind for MedSup demand that management highlighted but did not fully quantify in terms of addressable market expansion. This regulatory tailwind, combined with persistent demographic drivers (11,000 Americans turning 65 daily) and the company's exclusive middle-market focus, positions MedSup for both volume growth and pricing power that could meaningfully exceed current consensus expectations for margin improvement in the health segment.
The Worksites division is experiencing a structural inflection point driven by geographic expansion and new client acquisition, with NAP from new clients up 65% year-over-year—a metric that signals durable, scalable growth beyond cyclical fluctuations. Management noted that hospital indemnity insurance NAP surged 121% and life insurance NAP rose 56% in the division, directly tied to penetration into new markets and associations. This expansion is particularly significant given the Worksites business' four-year CAGR of 20% in Life and Health NAP, indicating that recent growth is not merely a rebound but part of a longer-term trend. The increase in producing agent count (up 3%) and registered agent count (up 7%) provides the distribution capacity to sustain this momentum, while the career agent model's resonance with applicants seeking financial stability reduces recruiting friction. Importantly, management emphasized that Live sales—particularly impactful in Worksites—experienced a significant uptick from new client relationships, suggesting higher conversion rates and stronger persistency. This geographic and demographic expansion into underserved small-to-mid-sized businesses creates a runway for double-digit NAP growth that could drive earnings acceleration well into FY27, especially as operating leverage kicks in from fixed cost bases.
CNO's strategic deployment of technology and AI in the Colonial Penn call center is generating tangible productivity gains that are underappreciated as a margin driver, with early results showing shorter customer wait times and higher sales conversion rates—directly contributing to improved expense efficiency and revenue quality. The company noted that nearly 65% of direct-to-consumer life sales now originate from non-television digital, web, or third-party channels, reflecting a successful shift away from costly TV advertising toward higher-ROI digital acquisition. This transition reduces customer acquisition costs while improving targeting precision, which should compound over time as AI models optimize lead routing and agent performance. Management framed these investments as part of a broader roadmap to drive agent productivity and customer experience, with multiple initiatives moving from pilot to execution. Given that the expense ratio improved to 18.9% in Q1 FY26 due to lower-than-planned spending (expected to normalize), the real bullish case lies in the possibility that technology-driven efficiency gains could structurally lower the long-term expense ratio baseline, thereby expanding operating margins beyond what current guidance implies. This operational leverage, combined with stable investment yields and disciplined capital deployment, could enable ROE expansion toward the 13-14% range sooner than anticipated, particularly if the company reinvests efficiency savings into growth initiatives rather than treating them as mere cost savings.
CNO Financial Group's Medicare Supplement (MedSup) business represents a significant underappreciated catalyst for sustained margin expansion, with approved rate increases set to drive meaningful earnings acceleration in the second half of 2026 and beyond. Management disclosed approvals for a 10.2% rate increase on the closed block (representing two-thirds of exposure) effective January 1, 2026, and expects approximately 14.5% approvals on the open block effective July 1, 2026. These increases are designed to address modestly adverse claims experience and will fully impact benefit ratios by Q4 FY26, with the potential to generate meaningful operating leverage as the company laps tougher comparables in subsequent quarters. Crucially, the shift away from Medicare Advantage—underscored by industry disruption where approximately 3 million MA members had plans terminated for 2026 and one in five beneficiaries switched plans during AEP—creates a structural tailwind for MedSup demand that management highlighted but did not fully quantify in terms of addressable market expansion. This regulatory tailwind, combined with persistent demographic drivers (11,000 Americans turning 65 daily) and the company's exclusive middle-market focus, positions MedSup for both volume growth and pricing power that could meaningfully exceed current consensus expectations for margin improvement in the health segment.
The Worksites division is experiencing a structural inflection point driven by geographic expansion and new client acquisition, with NAP from new clients up 65% year-over-year—a metric that signals durable, scalable growth beyond cyclical fluctuations. Management noted that hospital indemnity insurance NAP surged 121% and life insurance NAP rose 56% in the division, directly tied to penetration into new markets and associations. This expansion is particularly significant given the Worksites business' four-year CAGR of 20% in Life and Health NAP, indicating that recent growth is not merely a rebound but part of a longer-term trend. The increase in producing agent count (up 3%) and registered agent count (up 7%) provides the distribution capacity to sustain this momentum, while the career agent model's resonance with applicants seeking financial stability reduces recruiting friction. Importantly, management emphasized that Live sales—particularly impactful in Worksites—experienced a significant uptick from new client relationships, suggesting higher conversion rates and stronger persistency. This geographic and demographic expansion into underserved small-to-mid-sized businesses creates a runway for double-digit NAP growth that could drive earnings acceleration well into FY27, especially as operating leverage kicks in from fixed cost bases.
CNO's strategic deployment of technology and AI in the Colonial Penn call center is generating tangible productivity gains that are underappreciated as a margin driver, with early results showing shorter customer wait times and higher sales conversion rates—directly contributing to improved expense efficiency and revenue quality. The company noted that nearly 65% of direct-to-consumer life sales now originate from non-television digital, web, or third-party channels, reflecting a successful shift away from costly TV advertising toward higher-ROI digital acquisition. This transition reduces customer acquisition costs while improving targeting precision, which should compound over time as AI models optimize lead routing and agent performance. Management framed these investments as part of a broader roadmap to drive agent productivity and customer experience, with multiple initiatives moving from pilot to execution. Given that the expense ratio improved to 18.9% in Q1 FY26 due to lower-than-planned spending (expected to normalize), the real bullish case lies in the possibility that technology-driven efficiency gains could structurally lower the long-term expense ratio baseline, thereby expanding operating margins beyond what current guidance implies. This operational leverage, combined with stable investment yields and disciplined capital deployment, could enable ROE expansion toward the 13-14% range sooner than anticipated, particularly if the company reinvests efficiency savings into growth initiatives rather than treating them as mere cost savings.
CNO Financial Group faces meaningful headwinds in its annuity business that management dismissed as mere quarterly fluctuations, but which may signal deeper structural challenges in a rising rate environment despite the company's claims of strong underlying demand. While annuity collected premiums declined only 2% year-over-year, management attributed this to tough comparables and claimed indifference to short-term volume fluctuations, yet the concurrent 7% growth in annuity account values suggests that new sales weakness is being masked by persistency and market appreciation—a dynamic that could deteriorate if surrender rates rise or if consumers shift toward bank CDs and Treasuries offering competitive yields with less complexity. More critically, Eric Johnson acknowledged that credit spreads remain "pretty flat," limiting incremental return opportunities in the investment portfolio, and that the company maintained a conservative approach to FABN funding due to unfavorable arbitrage conditions during Q1 FY26. This constraint on spread income generation—combined with the fact that net investment income growth of 6% was driven equally by asset growth (4.8%) and yield improvement—suggests that further NII expansion will increasingly rely on growing the asset base rather than margin expansion, which may pressure ROE if asset growth slows or if new money yields fail to meaningfully exceed current levels. The company's reliance on new money rates above 6% for thirteen consecutive quarters may not be sustainable if monetary policy tightens further or if credit market dislocations reduce yield pickup opportunities, creating a potential ceiling on investment income growth that is not adequately priced into current expectations.
The expense ratio improvement to 18.9% in Q1 FY26 may be misleading and unsustainable, as management explicitly stated they expect normalization through the rest of the year, indicating that the current favorability is largely timing-related rather than structural. Paul McDonough noted that Q1 typically has higher expenses, which grade down over time, yet this year the inverse occurred—lower expenses in Q1 that are expected to rise. This deviation from historical seasonality suggests that the low expense ratio may reflect delayed spending or one-time savings rather than enduring efficiency gains, particularly given that the company has not cited specific, measurable cost-cutting initiatives beyond general discipline. Furthermore, while technology and AI investments are underway, their full financial impact remains unquantified and likely lagged, meaning any near-term expense benefits are likely coincidental rather than causal. If expenses revert to historical patterns or increase due to inflationary pressures on wages, technology maintenance, or agent commissions tied to strong sales growth, the operating leverage implied by the current expense ratio could reverse, squeezing margins even as top-line growth continues. This risk is amplified by the company's affirmation of original 2026 guidance despite Q1 outperformance, suggesting management itself does not view the current cost base as a new sustainable floor.
CNO's capital return strategy, while presently robust, contains latent risks tied to its reliance on share repurchases as a primary driver of EPS growth, which could become less effective or even detrimental if valuations decline or if regulatory capital requirements tighten unexpectedly. The company returned $77 million to shareholders in Q1 FY26, including $60 million in share repurchases that reduced diluted share count by 7%, a tactic that significantly boosted operating EPS growth (33% reported, 42% ex-items). However, with the consolidated RBC ratio already in the middle of the 360%-390% target range and holding company liquidity at $280 million (above the $150 million minimum), there is limited room for further aggressive capital deployment without risking a downgrade in financial flexibility. More concerning is Paul McDonough's acknowledgment that a 5% S&P decline in Q1 FY26 drove reserves down for FIAs and interest-sensitive life, creating statutory surplus volatility that impacted RBC—yet he assumed a neutral full-year impact contingent on equity market recovery. If markets fail to sustain recovery or if volatility persists, the company may be forced to pause repurchases to conserve capital, removing a key EPS tailwind. Additionally, the focus on buybacks over dividend growth—despite the 14th consecutive annual increase being only a $0.01 raise to $0.18 quarterly—suggests limited confidence in long-term free cash flow sustainability, raising questions about whether organic earnings growth can support both current dividends and aggressive repurchases without compromising investment in growth initiatives or credit metrics.
CNO Financial Group faces meaningful headwinds in its annuity business that management dismissed as mere quarterly fluctuations, but which may signal deeper structural challenges in a rising rate environment despite the company's claims of strong underlying demand. While annuity collected premiums declined only 2% year-over-year, management attributed this to tough comparables and claimed indifference to short-term volume fluctuations, yet the concurrent 7% growth in annuity account values suggests that new sales weakness is being masked by persistency and market appreciation—a dynamic that could deteriorate if surrender rates rise or if consumers shift toward bank CDs and Treasuries offering competitive yields with less complexity. More critically, Eric Johnson acknowledged that credit spreads remain "pretty flat," limiting incremental return opportunities in the investment portfolio, and that the company maintained a conservative approach to FABN funding due to unfavorable arbitrage conditions during Q1 FY26. This constraint on spread income generation—combined with the fact that net investment income growth of 6% was driven equally by asset growth (4.8%) and yield improvement—suggests that further NII expansion will increasingly rely on growing the asset base rather than margin expansion, which may pressure ROE if asset growth slows or if new money yields fail to meaningfully exceed current levels. The company's reliance on new money rates above 6% for thirteen consecutive quarters may not be sustainable if monetary policy tightens further or if credit market dislocations reduce yield pickup opportunities, creating a potential ceiling on investment income growth that is not adequately priced into current expectations.
The expense ratio improvement to 18.9% in Q1 FY26 may be misleading and unsustainable, as management explicitly stated they expect normalization through the rest of the year, indicating that the current favorability is largely timing-related rather than structural. Paul McDonough noted that Q1 typically has higher expenses, which grade down over time, yet this year the inverse occurred—lower expenses in Q1 that are expected to rise. This deviation from historical seasonality suggests that the low expense ratio may reflect delayed spending or one-time savings rather than enduring efficiency gains, particularly given that the company has not cited specific, measurable cost-cutting initiatives beyond general discipline. Furthermore, while technology and AI investments are underway, their full financial impact remains unquantified and likely lagged, meaning any near-term expense benefits are likely coincidental rather than causal. If expenses revert to historical patterns or increase due to inflationary pressures on wages, technology maintenance, or agent commissions tied to strong sales growth, the operating leverage implied by the current expense ratio could reverse, squeezing margins even as top-line growth continues. This risk is amplified by the company's affirmation of original 2026 guidance despite Q1 outperformance, suggesting management itself does not view the current cost base as a new sustainable floor.
CNO's capital return strategy, while presently robust, contains latent risks tied to its reliance on share repurchases as a primary driver of EPS growth, which could become less effective or even detrimental if valuations decline or if regulatory capital requirements tighten unexpectedly. The company returned $77 million to shareholders in Q1 FY26, including $60 million in share repurchases that reduced diluted share count by 7%, a tactic that significantly boosted operating EPS growth (33% reported, 42% ex-items). However, with the consolidated RBC ratio already in the middle of the 360%-390% target range and holding company liquidity at $280 million (above the $150 million minimum), there is limited room for further aggressive capital deployment without risking a downgrade in financial flexibility. More concerning is Paul McDonough's acknowledgment that a 5% S&P decline in Q1 FY26 drove reserves down for FIAs and interest-sensitive life, creating statutory surplus volatility that impacted RBC—yet he assumed a neutral full-year impact contingent on equity market recovery. If markets fail to sustain recovery or if volatility persists, the company may be forced to pause repurchases to conserve capital, removing a key EPS tailwind. Additionally, the focus on buybacks over dividend growth—despite the 14th consecutive annual increase being only a $0.01 raise to $0.18 quarterly—suggests limited confidence in long-term free cash flow sustainability, raising questions about whether organic earnings growth can support both current dividends and aggressive repurchases without compromising investment in growth initiatives or credit metrics.